Technology
Our Innovations Technology
Bridge-It® Assay Platform Technology
Mediomics’ novel DNA-binding protein assay design utilizes a two fluorophore system (a fluorophore donor and a fluorophore acceptor) in which the DNA fragment containing the binding site for the target…
TR-FRET Bridge-It® Assay Platform Technology
FRET-Pincer® Assay Platform Technology
FRET-PINCER® Assays are a unique system to quantify the concentration of biomarkers, cells, and pathogens in a broad range of biological samples. Mediomics’ PINCER® assay uses antibody binding …
TRF-Pincer® Assay Platform Technology
TRF-PINCER® Assays are a unique system to quantify the concentration of biomarkers, cells, and pathogens in a broad range of biological samples. Mediomics’ PINCER® assay uses antibody binding…
Exclusive Patent License
Mediomics, LLC holds an exclusive, worldwide license (with right to sublicense) for all possible commercial product applications covered by the claims of the issued and pending patents and patent applications invented in Dr. Tomasz Heyduk, Dr. Yie-Hwa Chang and Dr. David Waisman’s laboratories. This exclusive licensing agreement also provides to Mediomics an exclusive commercial license for all patents relating to the exclusively licensed patents, including any follow-on patents. Currently, Mediomics holds exclusive license for over 40 issued patents and pending patent applications (including any and all related patent filings).
Trademarks
The registered trademark, Bridge-It®, is owned by Mediomics. A trademark registration application for Mediomics trademark PincersTM is currently pending at the US-Patent and Trademark Office.